Papillary serous cystadenocarcinoma
Papillary Serous Cystadenocarcinoma[edit | edit source]
Papillary serous cystadenocarcinomas are the most prevalent form of malignant ovarian cancer, accounting for approximately 26 percent of ovarian tumors in women over the age of 20 in the United States. Characterized by their aggressive nature, these tumors often present challenges in early detection and treatment.
Overview[edit | edit source]
Papillary serous cystadenocarcinomas are known for their malignant potential and tendency to metastasize. They are commonly diagnosed in advanced stages, as early signs of the disease are typically absent. The spread of these tumors often occurs along the peritoneum, contributing to the complexity of treatment.
Histopathology[edit | edit source]
Histopathological examination of papillary serous cystadenocarcinomas can reveal distinct features such as:
- Psammoma bodies - Calcified structures that are often present in these types of tumors.
Diagnosis[edit | edit source]
Diagnosis of papillary serous cystadenocarcinoma typically involves a combination of:
- Pelvic examinations
- Imaging studies such as Ultrasound, CT scans, or MRI
- CA-125 blood test, which may show elevated levels in the presence of ovarian cancer
- Biopsy and histopathological analysis to confirm the presence of cancerous cells
Treatment[edit | edit source]
The standard treatment for papillary serous cystadenocarcinoma often includes:
- Surgery to remove as much of the tumor as possible
- Chemotherapy to target cancer cells that may have spread beyond the ovaries
- Targeted therapies and hormone therapies may also be used depending on the individual case and tumor characteristics
Prognosis[edit | edit source]
The prognosis for patients with papillary serous cystadenocarcinoma can vary based on the stage at diagnosis and the effectiveness of treatment. Generally, the five-year relative survival rate serves as a benchmark for prognosis, with early detection and treatment improving outcomes.
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
